Immunome Research

Immunome Research
Open Access

ISSN: 1745-7580

+32 28087017

Yusuf Muhammed

Department of Biochemistry Federal University Gusau, Zamafara State, Nigeria

  • Review Article   
    The Best IgG Subclass for the Development of Therapeutic Monoclonal Antibody Drugs and their Commercial Production: A Review
    Author(s): Yusuf Muhammed*

    Most of the clinically available monoclonal antibody (mAbs) drugs are Immunoglobulin G's (IgG's). The variability of the IgG subclasses is in the amino acid content of the hinge region which forms the basis of their stability and suitability for therapeutics development. Monoclonal antibody drug development is a tedious and long-term process requiring putting many factors into consideration. The variability in the stability, flexibility, mediation of antibody dependent cell cytotoxicity (ADCC), mediation of cellular dependent cytotoxicity (CDC), and C1q protein binding are major factors that determine the suitability of IgG subclasses for the development of therapeutics. It was reviewed that most of the marketed mAbs therapeutics are IgG1 subclass, this is due to its stability and less aggregate formation, triggering of effector function via the action of Fc domai.. Read More»
    DOI: 10.35248/1745-7580.20.16.173

    Abstract HTML PDF